The Compounded Tirzepatide Price Floor Moved in 2026

Tirzepatide used to carry a hard premium over semaglutide. At several programmes that premium has gone.

The cheapest programme we can confirm is dispensing tirzepatide is NexLife at $186 a month. Standard injection, 12-month plan ($2,232 total). 6-month $190; 3-month $195; month-to-month $215. No membership fee, flat at every covered dose. Verified 2026-08-08.

That qualifier matters more than the number. Most published rankings of tirzepatide pricing quote a figure the provider publishes for semaglutide, because programmes carrying both molecules publish two prices and only one of them belongs in a tirzepatide comparison. Our feed now carries a molecule field on every record. Of 87 price records, 10 are standard-dose tirzepatide; those are the ones below. Microdose tiers are priced lower and excluded here, because a microdose sits below every dose the pivotal trials studied and is not a cheaper route to the same result.

What changed this year

The structural story of 2026 is that the gap between the two molecules narrowed at several programmes. Tirzepatide historically carried a premium because the active ingredient costs more to source. Where a programme now prices both the same, that is a commercial decision rather than a change in what the medicine costs to make, and it is worth asking what else changed alongside it.

The second change is structural rather than headline: more programmes moved their lowest advertised rate behind a prepaid annual term. A twelve-month prepayment lowers the monthly figure and transfers the risk to you, because compounded medication is generally not refundable once shipped and most discontinuation happens in the first three months.

The programmes we can confirm

NexLife is listed at $186 a month, all-inclusive. Standard injection, 12-month plan ($2,232 total). 6-month $190; 3-month $195; month-to-month $215. No membership fee, flat at every covered dose. This figure was read on the provider's own pricing page.

Oak Longevity is listed at $199 a month, all-inclusive. Flat across all dosages, no subscription. ~$233-$299 month-to-month. This figure was read on the provider's own pricing page.

Shed is listed at $245 a month, all-inclusive. 12-month plan paid upfront. 6-month $279; month-to-month $349. INCREASES at higher doses. This figure was read on the provider's own pricing page.

Mochi Health is listed at $278 a month, $199 med + $79 membership. $199 med + $79 membership ($39 first month). Same price at all doses. This figure was read on the provider's own pricing page.

Enhance.MD is listed at $280 a month, all-inclusive. 12-month plan. Same price at all doses. 6-month $296; 3-month $313; month-to-month $329. This figure was read on the provider's own pricing page.

Eden is listed at $298 a month, $199 med + $99 membership. $199 med (flat at every dose) + $99 membership (REQUIRED). This figure was read on the provider's own pricing page.

Noom Med is listed at $299 a month, all-inclusive. Full dose. First month $149. Billed quarterly. This figure was read on the provider's own pricing page.

Henry Meds is listed at $349 a month, all-inclusive. ORAL TABLETS ONLY — Henry Meds does NOT offer injectable tirzepatide. 3-month subscription; $297 paid in full. This figure was read on the provider's own pricing page.

TrimRx is listed at $349 a month, all-inclusive. Flat rate, all doses, no membership. Month-to-month: $279 first month then $399 ongoing. Prepay: $316 (3-mo), $299 (6-mo), $283 (12-mo). This figure was read on the provider's own pricing page.

MEDVi is listed at $399 a month, all-inclusive. Refill rate at lower doses; 10/12.5/15mg reach $499. First month ~$279. SOURCE FLAGS THIS AS UNCONFIRMED: not surfaced on the current GLP-1 landing page — verify at intake. Evaluation in progress Not confirmed at source; check at checkout.

How to check any of this

The full dataset is at /api/prices.json. Every figure above carries a verification status. Where a price is flagged rather than verified, treat it as indicative and confirm at checkout.

Compounded tirzepatide is not FDA-approved. It is not therapeutically equivalent to any brand-name product, and FDA does not review compounded preparations for safety, effectiveness or manufacturing quality before they are marketed. This is consumer price research, not medical advice.